Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Linrodostat Free Base vs Reference Tablet
NCT03378310Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linrodostat in solid tumor (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-Time Curve. Started Dec 2017; status: completed.
02
Drugs
linrodostat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03378310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03378310.